Business Standard

Moderna CEO targets emergency use for Covid-19 vaccine by December

CEO Stephane Bancel expects interim results of vaccine trial by November, the Wall Street Journal reported

Vaccine
Premium

The first interim analysis of the vaccine's efficacy will happen when 53 people in the entire study get symptomatic Covid-19, the report said

Anirudh Saligrama | Reuters Bengaluru
Moderna’s Chief Executive Officer Stephane Bancel expects interim results from its Covid-19 vaccine trial in November, and if all goes well, said the US government could give an emergency use nod in December, the Wall Street Journal reported on Monday.
Speaking at the newspaper's annual Tech Live conference, Bancel also said sufficient interim results from the study takes longer to get and that the government's permission to use the vaccine may not come until next year.
 
The first interim analysis of the vaccine's efficacy will happen when 53 people in the entire study get symptomatic Covid-19, the report said.
 
“That first

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in